A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Clinical trial NCT03222609 · COMPLETED

Trial details

NCT number: NCT03222609
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelofibrosis (MF)

Start date: 2017-10-31
Primary completion: 2022-03-28
Enrollment: 191

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.